Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Meihong Zheng, Xuan Zhou, Qien Wang, Xin Chen, Bei Cao & Juan Li. (2021) Metabolomic approach to characterize the metabolic phenotypes and varied response to ouabain of diffuse large B-cell lymphoma cells. Leukemia & Lymphoma 62:7, pages 1597-1608.
Read now
Read now
Lauren Held, Chloe Siu & Mazyar Shadman. (2021) Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far. Expert Opinion on Pharmacotherapy 22:6, pages 655-665.
Read now
Read now
Sonal Agarwal, Andrew Kowalski, Molly Schiffer, Jennifer Zhao, Jan Philipp Bewersdorf & Amer M. Zeidan. (2021) Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. Expert Review of Hematology 14:2, pages 199-210.
Read now
Read now
Anna Korycka-Wolowiec, Dariusz Wolowiec, Aleksandra Kubiak-Mlonka & Tadeusz Robak. (2019) Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism & Toxicology 15:5, pages 353-366.
Read now
Read now
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, Mignon L Loh, Lia Gore, Daniel A Morgenstern, Yeshwant Sanzgiri, David Hoffman, Ying Zhou, Jeremy A Ross, Betty Prine, Mohamad Shebley, Megan McNamee, Thalia Farazi, Su Young Kim, Maria Verdugo, Leanne Lash-Fleming, C Michel Zwaan & Josef Vormoor. (2018) Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies. Future Oncology 14:21, pages 2115-2129.
Read now
Read now
Articles from other publishers (20)
Laura Giuseppina Di Pasqua, Murwan Mahmoud Abdallah, Fausto Feletti, Mariapia Vairetti & Andrea Ferrigno. (2024) Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management. Pharmaceuticals 17:4, pages 484.
Crossref
Crossref
Weibin Fan, Jun Guo, Yue Zhang, Runcong Zhang & Bin Lin. (2024) Venetoclax dose adjustment due to drug-drug interactions: a case report and literature review. Anti-Cancer Drugs 35:1, pages 70-75.
Crossref
Crossref
Claudia Cerella, Sruthi Reddy Gajulapalli, Anne Lorant, Deborah Gerard, Florian Muller, Yejin Lee, Kyung Rok Kim, Byung Woo Han, Christo Christov, Christian Récher, Jean-Emmanuel Sarry, Mario Dicato & Marc Diederich. (2023) ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. Leukemia 38:1, pages 67-81.
Crossref
Crossref
Andaleeb Sajid, Hadiar Rahman & Suresh V. Ambudkar. (2023) Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nature Reviews Cancer 23:11, pages 762-779.
Crossref
Crossref
Melanie A. Felmlee, Michael Ng & Annie Lee. 2023. Oral Bioavailability and Drug Delivery. Oral Bioavailability and Drug Delivery
339
360
.
Benoit Cox, Johan Nicolaï & Beth Williamson. (2022) The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery. Biopharmaceutics & Drug Disposition 44:1, pages 113-126.
Crossref
Crossref
Arpita Gandhi, Benjamin Andrick, Julianne Darling, Tuyet Truong & Jessie Signorelli. (2022) Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review. Clinical Lymphoma Myeloma and Leukemia 22:12, pages e1033-e1049.
Crossref
Crossref
Athar Husain, Vishal Makadia, Guru R. Valicherla, Mohammed Riyazuddin & Jiaur R. Gayen. (2022) Approaches to minimize the effects of P‐glycoprotein in drug transport: A review. Drug Development Research 83:4, pages 825-841.
Crossref
Crossref
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B. Douglas Smith, Andrew H. Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan & Jiuhong Zha. (2022) Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematological Oncology 40:2, pages 269-279.
Crossref
Crossref
Eliza R. McColl, Vessela Vassileva & Micheline Piquette-Miller. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
608
626
.
May Levin, Michal Stark, Yishai Ofran & Yehuda G. Assaraf. (2021) Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance. Cancer Cell International 21:1.
Crossref
Crossref
Chong Chyn Chua, Andrew W. Roberts, John Reynolds, Chun Yew Fong, Stephen B. Ting, Jessica M. Salmon, Sarah MacRaild, Adam Ivey, Ing Soo Tiong, Shaun Fleming, Fiona C. Brown, Sun Loo, Ian J. Majewski, Stefan K. Bohlander & Andrew H. Wei. (2020) Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. Journal of Clinical Oncology 38:30, pages 3506-3517.
Crossref
Crossref
Juan Eduardo Megías-Vericat, Antonio Solana-Altabella, Octavio Ballesta-López, David Martínez-Cuadrón & Pau Montesinos. (2020) Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Annals of Hematology 99:9, pages 1989-2007.
Crossref
Crossref
Ali A. Alhadab, Ahmed Hamed Salem & Kevin J. Freise. (2020) Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science 13:3, pages 555-562.
Crossref
Crossref
Nikki Blosser, Jennifer Jupp, Patrick Yau & Douglas Stewart. (2019) Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. Clinical Pharmacokinetics 59:1, pages 7-23.
Crossref
Crossref
Nimita Dave, Sathej Gopalakrishnan, Sven Mensing & Ahmed Hamed Salem. (2019) Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis. Clinical and Translational Science 12:6, pages 625-632.
Crossref
Crossref
Ahmed Hamed Salem, Nimita Dave, Thomas Marbury, Beibei Hu, Dale Miles, Suresh K. Agarwal, Orlando F. Bueno & Rajeev M. Menon. (2019) Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clinical Pharmacokinetics 58:8, pages 1091-1100.
Crossref
Crossref
Suresh K. Agarwal, Bo Tong, Orlando F. Bueno, Rajeev M. Menon & Ahmed Hamed Salem. (2018) Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Advances in Therapy 35:11, pages 2015-2023.
Crossref
Crossref
Takashi Matsumoto, Noriko Kaifuchi, Yasuharu Mizuhara, Eiji Warabi & Junko Watanabe. (2018) Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein. Journal of Natural Medicines 72:4, pages 897-904.
Crossref
Crossref
Kevin J. Freise, Beibei Hu & Ahmed Hamed Salem. (2018) Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. European Journal of Clinical Pharmacology 74:4, pages 413-421.
Crossref
Crossref